Treace Medical Concepts, Inc. (TMCI) Guidance & Earnings Results

On 2026-08-07 Treace Medical Concepts, Inc. raised guidance: "Revenue guidance raised to $204-212M from $202-212M; Adjusted EBITDA loss guidance improved to $3-5M from…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

TMCITreace Medical Concepts, Inc.Follow TMCI — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 277.7M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 10 Nov, in 17 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
7 Aug 26	Raised	Revenue guidance raised to $204-212M from $202-212M; Adjusted EBITDA loss guidance improved to $3-5M from $4-6M · full year
8 May 26	Reaffirmed	FY26 revenue $202-212M; FY26 adj EBITDA loss $(4-6)M; FY26 cash usage reduction ~50% vs FY25 · full year
9 Apr 26	Raised	FY2026 revenue raised to $202-212M from $200-212M · full year
27 Feb 26	Lowered	FY2026 revenue $200-212M (decline 6-0% vs FY2025 $212.7M); FY2026 adjusted EBITDA loss $4-6M (vs FY2025 loss $3.9M); FY2026 cash usage reduction ~50% (vs FY2025 $27.3M) · full year
6 Nov 25	Lowered	FY2025 revenue cut to $211-213M from $224-230M; FY2025 adjusted EBITDA loss guided to $(6.5-7.5)M from breakeven; cash used reduction revised to 43-47% from 50% · full year
7 Aug 25	Reaffirmed	FY25 revenue $224-230M; FY25 breakeven adjusted EBITDA · full year

Treace Medical Concepts, Inc. — questions

What guidance did Treace Medical Concepts, Inc. give?: On 2026-08-07: "Revenue guidance raised to $204-212M from $202-212M; Adjusted EBITDA loss guidance improved to $3-5M from $4-6M"
When does Treace Medical Concepts, Inc. report earnings?: Treace Medical Concepts, Inc.'s next earnings report is expected on 2026-11-10.

Every figure on this page comes from Treace Medical Concepts, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.